Please assess the completion status of the following clinical trial:

Trial Title: Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Criteria:~* Histologically confirmed adenocarcinoma of the prostate~* Clinical stage T1c or T2 (stage II)~* Gleason score of 6 or 7 on initial biopsy~* Prostate-specific antigen (PSA) level less than 10 ng/mL within the past 3 months~* Candidate for and scheduled to undergo prostatectomy~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 70-100%~* Fertile patients must use effective contraception~* No active malignancy at any other site~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to finasteride~* No uncontrolled intercurrent illness including, but not limited to, any of the following: Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia~* No psychiatric illness or social situation that would preclude study compliance~* More than 6 months since prior hormonal agents, including dutasteride or finasteride~* More than 6 months since prior chemotherapy~* More than 1 month since prior participation in another investigational study~* No prior radiotherapy for the primary tumor~* No concurrent dehydroepiandrosterone, phytoestrogen supplements, antiandrogen therapy, dutasteride, or other finasteride~* No concurrent anticoagulation, except for the use of daily acetylsalicylic acid (81 mg to 325 mg)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Finasteride) (Type: EXPERIMENTAL): Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
- Arm II (Placebo) (Type: PLACEBO_COMPARATOR): Placebo once daily for 4-6 weeks, then undergo prostatectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).